Other
CN
EU
USA
Description: Brinzolamide (formerly also known as AL-4862) is a highly potent and selective carbonic anhydrase II inhibitor with IC50 of 3.19 nM.
References: Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29; Ophthalmol. 2000 Jan;44 Suppl 2:S147-53.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Brinzolamide is the newest topical CAI to be successfully developed and marketed. It is a safe and efficacious glaucoma drug. In the in vitro assay, brinzolamide has its highest affinity (Ki of 0.13nM) and inhibitory potency (IC50 of 3.19 nM) for CA-II. It has much higher affinity and greater potency for CA-II than for CA-I and CAIV. In the in vivo models, administration of brinzolamide significantly reduces the intraocular pressure (IOP) both in the pigmented rabbits and cynomolgus monkeys with ocular hypertension induced by argon laser trabeculoplasty.
Kinase Assay: Brinzolamide(AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.
Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29; Surv Ophthalmol. 2000 Jan;44 Suppl 2:S147-53.
Purity ≥98%
COA
MSDS
NMR